Last $6.70 USD
Change Today +0.10 / 1.52%
Volume 14.0K
LBIO On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 5:20 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

lion biotechnologies inc (LBIO) Snapshot

Open
$6.50
Previous Close
$6.60
Day High
$6.70
Day Low
$6.50
52 Week High
10/4/13 - $18.00
52 Week Low
10/31/13 - $3.18
Market Cap
182.4M
Average Volume 10 Days
9.6K
EPS TTM
--
Shares Outstanding
27.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for LION BIOTECHNOLOGIES INC (LBIO)

Related News

No related news articles were found.

lion biotechnologies inc (LBIO) Related Businessweek News

No Related Businessweek News Found

lion biotechnologies inc (LBIO) Details

Lion Biotechnologies, Inc., a development stage biotechnology company, develops T-cells and engineered T-cells for the treatment of various cancers. The company’s lead product candidate includes a ready-to-infuse autologous T-cell therapy using tumor-infiltrating lymphocytes (TILs) for the treatment of patients with stage IV metastatic melanoma. It has a patent license agreement with the National Institutes of Health to develop and manufacture certain proprietary autologous TILs adoptive cell therapy products for the treatment of metastatic melanoma, ovarian cancer, breast cancer, and colorectal cancer; a cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that destroy metastatic melanoma cells using a patient’s tumor infiltrating lymphocytes; and a process development and scale-up consulting agreement with Lonza Walkersville, Inc. to manufacture TILs. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in Woodland Hills, California.

5 Employees
Last Reported Date: 03/28/14
Founded in 2007

lion biotechnologies inc (LBIO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $66.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $180.0K
Compensation as of Fiscal Year 2013.

lion biotechnologies inc (LBIO) Key Developments

Lion Biotechnologies, Inc. Hires Elma Hawkins as President and Chief Operating Officer

Lion Biotechnologies, Inc. has hired Elma Hawkins, PhD, MBA, to serve as president and chief operating officer. Her appointment is effective immediately. Having served as Lion's head of clinical development since February 2014, Dr. Hawkins has more than 30 years of experience in biotechnology drug development, corporate development, fundraising and general management, with a special focus on oncology. For the past eight years, she has consulted for various biotechnology companies and financial institutions, and she also served as president of Viridian Pharmaceuticals.

Lion Biotechnologies Inc. Plans $5 Million Investment in Tampa, Will Focus on Cancer Research

Lion Biotechnologies Inc. estimates that it will incur more than $5 million of expense during the next two years in connection with the construction, furbishment and operation of the Tampa research facility, according to the company's quarterly filing with the U.S. Securities and Exchange Commission. The company is spending about $500,000 on the buildout of the 5,200-square-foot facility at 3802 Spectrum Blvd., and also plans to buy laboratory equipment and supplies, the filing said. Lion expects to the lab to ready for use by the end of October.

Lion Biotechnologies Announces Exclusive License Agreement with Moffitt Cancer Center

Lion Biotechnologies, Inc. announced that it has entered into an exclusive, worldwide license agreement with Moffitt Cancer Center. Under the terms of the agreement, Lion has licensed from Moffitt the rights to develop and commercialize new technologies to enhance TIL production from melanoma, which may be applicable to other tumor types that historically have not produced therapeutic TILs. The license is based on two provisional patent applications, filed under Compositions and Methods for Improving Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LBIO:US $6.70 USD +0.10

LBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for LBIO.
View Industry Companies
 

Industry Analysis

LBIO

Industry Average

Valuation LBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LION BIOTECHNOLOGIES INC, please visit www.genesis-biopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.